Therapeutic peptides started with insulin in 1922, when its discovery turned type 1 diabetes from a fatal disease into a manageable one. That breakthrough proved a peptide could be a drug, and the century since has been a steady march from animal-sourced extracts to engineered molecules made in the lab. The GLP-1 weight medications dominating headlines today sit at the far end of that hundred-year line.<\/p>\n
This is the story of how peptides became medicines. It runs through insulin, the chemistry that let scientists build peptides from scratch, the recombinant DNA revolution, and the modern era where some peptides are proven drugs and others remain experimental.<\/p>\n
At TrimRx, we believe understanding where peptide medicine came from helps you judge what is established and what is still hopeful. If a peptide or GLP-1 program might fit your goals, you can take the free assessment quiz to see where you stand.<\/p>\n
At TrimRx, we believe that understanding your options is the first step toward a more manageable health journey. You can take the free assessment quiz if you’re ready to see whether a personalized program is a fit for you.<\/p>\n
The history starts with insulin because it was the first peptide used as a drug, isolated in 1922 by Banting, Best, and colleagues in Toronto.<\/strong> It transformed type 1 diabetes from a death sentence into a treatable condition almost overnight.<\/p>\n Quick Answer: Therapeutic peptides began with insulin in 1922, the first peptide drug and one of the most important medical advances of the century.<\/p>\n Insulin proved the principle that a peptide hormone could be extracted, purified, and injected to replace what a body lacked. The first insulin came from animal pancreases, cattle and pigs, since there was no other way to obtain it. Patients who would have died within months lived for decades. The achievement won a Nobel Prize and set the template for an entire field: find the peptide that does the job, then figure out how to make enough of it safely.<\/p>\n Early therapeutic peptides were extracted from animal tissue, which was slow, expensive, and limited by supply.<\/strong> Animal insulin worked but differed slightly from the human version, occasionally causing reactions, and gathering it required enormous quantities of animal pancreas.<\/p>\n This extraction era lasted decades. Hormones like insulin and later growth hormone came from animal or human tissue, with all the limits that implied. Human growth hormone, for instance, was once collected from cadaver pituitary glands, a practice that ended after safety concerns. The bottleneck was always supply and purity. As long as peptides had to be harvested from tissue, the field could only grow so far. The next breakthroughs came from learning to build peptides without animals at all.<\/p>\n Solid-phase peptide synthesis, developed by Bruce Merrifield in the 1960s, is a method for building a peptide chain one amino acid at a time on a solid support bead.<\/strong> It made synthesizing peptides in the lab practical and reproducible, and it won Merrifield a Nobel Prize.<\/p>\n The technique anchored the first amino acid to a resin bead, then added each subsequent one in sequence, washing away byproducts between steps. This turned peptide synthesis from an art into something closer to an assembly line. It is still the foundation of how research and pharmaceutical peptides are made today, including the active ingredients that compounding pharmacies later turn into finished products. Merrifield’s method freed peptide medicine from its dependence on animal tissue for the molecules that could be built chemically.<\/p>\n Recombinant DNA technology, emerging in the late 1970s, let scientists insert a human gene into bacteria or yeast and have those organisms produce the peptide.<\/strong> This made human insulin available without animals and opened the door to producing many peptides at scale.<\/p>\n Human insulin made through recombinant DNA reached patients in the early 1980s, ending reliance on animal sources for that drug. The same approach allowed production of human growth hormone, clotting factors, and other peptide and protein drugs. For larger molecules that were impractical to synthesize chemically, recombinant production was the answer. Between solid-phase synthesis for smaller peptides and recombinant DNA for larger ones, the field finally had reliable ways to make almost any peptide it needed.<\/p>\n The GLP-1 drugs are the most recent blockbuster chapter, built on everything that came before.<\/strong> They use synthetic and engineered peptides, designed with chemical modifications to last far longer than the natural hormone, and they reached massive scale in the 2020s.<\/p>\n The GLP-1 story has its own roots, including a peptide from Gila monster venom that seeded the first drug, exenatide, in 2005. Later drugs like semaglutide, studied in the STEP trials (Wilding 2021, NEJM), and tirzepatide, studied in SURMOUNT-1 (Jastreboff 2022, NEJM), used albumin-binding fatty acid chains to achieve weekly dosing. These are peptide drugs in the fullest sense, descendants of insulin a century later, now defined as much by weight management as by diabetes.<\/p>\n Beyond insulin and the GLP-1 class, important peptide drugs include hormones like oxytocin and growth hormone, peptide antibiotics, and targeted therapies for specific conditions.<\/strong> The field is broad, spanning many areas of medicine.<\/p>\n Oxytocin is used in childbirth. Growth hormone treats certain growth disorders. Peptide antibiotics like polymyxins fight resistant infections. Tesamorelin, a growth hormone-releasing hormone analog, holds FDA approval for a specific HIV-related fat condition, and bremelanotide, known as PT-141, is approved for a sexual health indication. These show that peptides are not a single category but a tool used across medicine, with each established drug backed by clinical trials and regulatory approval.<\/p>\n Key Takeaway: Solid-phase peptide synthesis, developed by Merrifield in the 1960s, made building peptides one amino acid at a time practical.<\/p>\n Many newer peptides marketed for recovery, longevity, or performance have limited human data because they were never put through the rigorous trials that approved drugs require.<\/strong> Animal studies or small pilot trials may exist, but they do not prove safety or effectiveness in people.<\/p>\n This is the honest caveat the field demands. Peptides like BPC-157, with most evidence from animal work traced to Sikiric and colleagues, or GHK-Cu, studied largely in topical and lab settings by Pickart and others, are widely sold despite thin human data. BPC-157 was removed from the FDA’s Category 2 bulk substances list in April 2026, a regulatory change that did not add human trial evidence. The gap between what is marketed and what is proven is real, and a responsible source flags limited human data rather than implying these peptides match the evidence behind insulin or GLP-1 drugs.<\/p>\n Peptide drugs grew from a single medicine, insulin, into a major class over the twentieth century as new hormones were identified and new ways to make them emerged.<\/strong> By the 2000s, peptides were established across diabetes, endocrinology, and other fields.<\/p>\n The growth tracked the science. Each decade brought better methods to discover, synthesize, and produce peptides, which expanded what was possible. Insulin analogs improved blood sugar control. Growth hormone treated growth disorders once recombinant production made it safe and plentiful. Peptide hormones found roles in fertility, bone health, and more. The field matured from a one-drug story into a broad toolkit, setting the stage for the GLP-1 boom. That boom did not come from nowhere. It rested on a century of accumulated knowledge about how to turn peptides into reliable, scalable medicines, and on the regulatory framework built to test and approve them.<\/p>\n The future points toward more engineered peptides, better delivery methods like oral and long-acting forms, and combinations that hit multiple targets, as tirzepatide already does.<\/strong> Research continues across metabolism, immunity, and aging.<\/p>\n Delivery is a major frontier. Getting peptides to survive the stomach for oral dosing, as oral semaglutide achieved, opens new possibilities. Multi-target molecules that engage several receptors at once may extend the success of the twincretin approach. At the same time, the field faces pressure to bring rigorous evidence to the many peptides currently sold ahead of their data. The next century of peptide medicine will likely be defined by both new engineering and a sorting of which experimental peptides actually earn the proof.<\/p>\n Longer-acting forms are another active area. The albumin-binding trick that gave semaglutide its weekly schedule may be applied to other peptides, and researchers are exploring depot formulations that release a peptide steadily over weeks or months. Combined with better oral delivery, these advances could make peptide treatment far more convenient than the daily or weekly injections most patients use now. The throughline across a hundred years remains the same. Each breakthrough has been about making peptides easier to produce, last longer, and reach the patient in a form they can actually use.<\/p>\n From insulin in 1922 to the engineered GLP-1 drugs of today, peptide medicine has always advanced by solving the problem of how to make and deliver these molecules reliably.<\/strong> The established drugs carry trial evidence and approval. Many newer ones do not yet. A TrimRX clinician can tell you which peptides have the evidence to support their claims and which remain experimental, which is exactly the conversation the free assessment quiz opens.<\/p>\n Insulin, isolated in 1922 by Banting, Best, and colleagues in Toronto. It was the first peptide used as a drug and transformed type 1 diabetes from a fatal disease into a manageable one. Its success proved that a peptide hormone could be extracted, purified, and injected to treat disease, founding the entire field.<\/p>\n Two main ways. Smaller peptides are built chemically through solid-phase peptide synthesis, adding one amino acid at a time on a solid bead, a method developed by Merrifield in the 1960s. Larger ones are produced using recombinant DNA, where bacteria or yeast carrying a human gene make the peptide. Animal extraction is now rare.<\/p>\n Because it proved the concept. Before insulin, no one had used a peptide as a drug. Its success in 1922 showed that replacing a missing hormone could save lives and set the template for the field. Every peptide drug since, including the GLP-1 medications, descends from that breakthrough.<\/p>\n No. Established peptides like insulin and the GLP-1 drugs have rigorous trial evidence and FDA approval. Many newer peptides sold for recovery or longevity have only animal studies or small pilot trials, meaning limited human data. Honest sources flag this gap rather than implying all peptides carry the same evidence.<\/p>\n BPC-157 was removed from the FDA’s Category 2 bulk substances list in April 2026, which affected its compounding status. This was a regulatory change, not new clinical evidence. Most of BPC-157’s data still comes from animal studies, much of it from Sikiric and colleagues, so its human evidence remains limited.<\/p>\n Both are peptide drugs, separated by a century of advances. Insulin was the first, extracted from animal tissue in 1922. The GLP-1 drugs are engineered synthetic peptides designed to last for days, reaching scale in the 2020s. They share the same fundamental idea: use a peptide to correct a metabolic problem.<\/p>\n Disclaimer:<\/strong> This content is for informational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any disease or condition. Individual results may vary. Always consult a qualified healthcare professional before starting any weight loss program or medication.<\/p>\n","protected":false},"excerpt":{"rendered":" Therapeutic peptides started with insulin in 1922, when its discovery turned type 1 diabetes from a fatal disease into a manageable one.<\/p>\n","protected":false},"author":11,"featured_media":106294,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"_yoast_wpseo_title":"","_yoast_wpseo_metadesc":"","_yoast_wpseo_focuskw":"","footnotes":"","_flyrank_wpseo_metadesc":""},"categories":[19],"tags":[],"class_list":["post-106295","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-longevity"],"_links":{"self":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/106295","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/users\/11"}],"replies":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/comments?post=106295"}],"version-history":[{"count":1,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/106295\/revisions"}],"predecessor-version":[{"id":108008,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/106295\/revisions\/108008"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/media\/106294"}],"wp:attachment":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/media?parent=106295"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/categories?post=106295"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/tags?post=106295"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}How Were Early Peptides Made?<\/h2>\n
What Was Solid-phase Peptide Synthesis?<\/h2>\n
How Did Recombinant DNA Change Peptide Medicine?<\/h2>\n
Where Do the GLP-1 Drugs Fit in This History?<\/h2>\n
What Other Peptides Became Important Drugs?<\/h2>\n
Why Do Many Newer Peptides Have Limited Evidence?<\/h2>\n
How Did Peptide Drugs Grow Into a Major Class?<\/h2>\n
What Does the Future of Peptide Medicine Look Like?<\/h2>\n
The Path Forward with Peptides<\/h2>\n
FAQ<\/h2>\n
What Was the First Therapeutic Peptide?<\/h3>\n
How Are Peptides Made Today?<\/h3>\n
Why Is Insulin So Important to Peptide History?<\/h3>\n
Are All Marketed Peptides Backed by Strong Evidence?<\/h3>\n
What Happened with BPC-157 in 2026?<\/h3>\n
How Do the GLP-1 Drugs Connect to Insulin?<\/h3>\n